← 홈

전체 프로그램

ADC 1032 · Antibody 4684 · CGT 2713 · 다음 갱신 D-13 · 마지막 7월 31일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,531개
AntibodystaleNorthwestern UniversityPhase 1

Transferrin Receptor-Targeted Liposomal p53 cDNA (Transferrin Receptor-Targeted Liposomal p53 cDNA)

Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + 5FU/LV)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 71.7%임상시험 1상태 RECRUITING
ADCBiologicstaleYonsei UniversityPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleEli LillyApproved

Treatment of Encorafenib & Binimetinib & Cetuximab (Treatment of Encorafenib & Binimetinib & Cetuximab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRabin Medical CenterPreclinical

adalimumab (Humira, Treatment with Adalimumab)

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleChanghai HospitalPhase 2

TURBT (Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor, Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT))

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

MEDI4736 (Tremelimumab Plus Durvalumab, Tremelimumab Plus Durvalumab (MEDI4736))

Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Tremelimumab immunotherapy (Tremelimumab immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 3.1%임상시험 1상태 ACTIVE
AntibodystaleJanssenApproved

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab (Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleTimmune Biotech Inc.Phase 2

TriCAR-T-CD19 (TriCAR-T-CD19)

Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
AntibodystaleRocheApproved

Triamcinolone + Bevacizumab (Triamcinolone + Bevacizumab)

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Triamcinolone Acetonide and Bevacizumab (Triamcinolone Acetonide and Bevacizumab)

Diffuse Diabetic Macular Edema · Diffuse Diabetic Macular Edema

#DiffuseDiabeticMacularEdema#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleChia Tai Tianqing Pharmaceutica…Phase 3

Trifluridine /Tipiracil (TAS-102, Trifluridine /Tipiracil, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets)

HER2 IHC3+ Advanced Colorectal Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

TAS-102 (Trifluridine/tipiracil, Trifluridine/tipiracil (TAS-102))

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Dynamic Tumor Resistance

#DynamicTumorResistance#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Trifluridine/tipiracil (TAS-102, Trifluridine/tipiracil, Trifluridine/tipiracil (TAS-102) plus bevacizumab)

Colo-rectal Cancer; Third-line and Beyond Therapy · Colo-rectal Cancer

#Colo-rectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

159 / 177 페이지

← 이전다음 →